Rituximab-Conjugated DART Nanoformulation for CD20-Targeted Drug Delivery in Non-Hodgkin Lymphoma. (PubMed, Int J Nanomedicine) - Sep 22, 2026 - "To develop rituximab (RTX)-conjugated decreased nonspecific adhesivity receptor-targeted (DART) nanoparticles for CD20-targeted paclitaxel (PTX) delivery in non-Hodgkin lymphoma (NHL) and evaluate their targeting, therapeutic activity, formulation stability, and immune-associated cellular responses. These findings support RTX-DART/PTX as a proof-of-concept CD20-targeted nanomedicine strategy for systemic NHL. Further validation in additional lymphoma models, immunocompetent or humanized systems, and pharmacokinetic and biodistribution studies is required."
Journal • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology • CALR • IGF1
|
|
Alonso Heredia; Anthony J Kim; Byoungjae Kong; Daiheon Lee; Eduar Fernando Pinzon Burgos; Jung Soo Suk; Md Musavvir Mahmud
|